<DOC>
	<DOCNO>NCT01919047</DOCNO>
	<brief_summary>This study determine follow information . 1 . The occurrence adverse drug reaction clinical setting . 2 . Factors potentially impact safety , effectiveness , aspect .</brief_summary>
	<brief_title>Drug Use-Results Survey Betanis Tablets Japan</brief_title>
	<detailed_description>This survey aim determine follow information need conduct specified drug use-results survey post-marketing clinical study patient use Betanis ( generic name : mirabegron ) : 1 . The occurrence adverse drug reaction clinical setting . 2 . Factors potentially impact safety , effectiveness , aspect . Items Particular Interest : - Safety effectiveness patient hepatic impairment patient renal impairment . - Safety effectiveness mirabegron use concomitantly drug ( α1 blocker , anticholinergic agent , 5α reductase inhibitor , drug potent CYP3A4-inhibiting effect , drug CYP3A4-inducing effect , drug metabolize primarily CYP2D6 , frequently use drug ) . - The occurrence cardiovascular adverse event . - The occurrence adverse event relate increase intraocular pressure . - The occurrence urinary retention</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients receive mirabegron first time treatment urinary urgency , daytime frequency , urgency incontinence associate overactive bladder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>mirabegron</keyword>
	<keyword>occurrence adverse event</keyword>
	<keyword>Overactive Bladder Symptom Score</keyword>
</DOC>